Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib in Adult NF1-Associated Inoperable Plexiform Neurofibromas
NCT05331105Phase 2Recruiting
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib in plexiform neurofibroma (PN), sponsored by Shanghai KeChow Pharmaceuticals. Started Oct 2021; status: recruiting.
02
Drugs
tunlametinib
03
Conditions
plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT05331105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05331105.